🇺🇸 FDA
Pipeline program

SB-318

SB-318-1502

Phase 2 mab terminated

Quick answer

SB-318 for MPS I is a Phase 2 program (mab) at SANGAMO THERAPEUTICS, INC with 1 ClinicalTrials.gov record(s).

Program details

Company
SANGAMO THERAPEUTICS, INC
Indication
MPS I
Phase
Phase 2
Modality
mab
Status
terminated

Clinical trials